Plasma Fractionation Market by Product (Immunoglobulins [Intravenous, Subcutaneous], Albumin, Protease Inhibitors, VWF), Application (Preclinical, Therapeutics), Therapy (Neurology, Immunology, Hematology, Rheumatology), Region - Global Forecast to 2031

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN PLASMA FRACTIONATION MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 PLASMA FRACTIONATION MARKET OVERVIEW
• 3.2 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION
• 3.3 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 PLASMA FRACTIONATION MARKET SHARE, BY PRODUCT, 2026 VS. 2031 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing demand for immunoglobulins across immunology and neurology
    • 4.2.1.2 Strategic expansion of plasma collection capacity by market players
      • 4.2.1.2.1 Plasma collection-by volume
        • 4.2.1.2.1.1 US
        • 4.2.1.2.1.2 Canada
        • 4.2.1.2.1.3 United Kingdom
        • 4.2.1.2.1.4 Japan
        • 4.2.1.2.1.5 India
        • 4.2.1.2.1.6 Brazil
    • 4.2.1.3 Growing prevalence of respiratory diseases and alpha-

1 antitrypsin deficiency

• 4.2.1.4 Increasing utilization of albumin in critical care
• 4.2.2 RESTRAINTS
  • 4.2.2.1 High treatment costs and reimbursement constraints for plasma-derived products
  • 4.2.2.2 Market disruption caused by recombinant alternatives
• 4.2.3 OPPORTUNITIES
  • 4.2.3.1 Government strategies for increasing regional self-sufficiency in plasma fractionation
• 4.2.4 CHALLENGES
  • 4.2.4.1 Stringent government regulations for maintaining safety and quality of plasma-derived products
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 THREAT OF NEW ENTRANTS
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL BIOPHARMA INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
  • 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023-2025
  • 5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT SCENARIO (HS CODE 3002.12)
  • 5.6.2 EXPORT SCENARIO (HS CODE 3002.12)
• 5.7 KEY CONFERENCES & EVENTS, 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 INVESTMENT & FUNDING SCENARIO
• 5.10 CASE STUDY ANALYSIS
  • 5.10.1 UK APPROVES DOMESTIC PLASMA FOR FIVE ADDITIONAL PDMPS
  • 5.10.2 TAKEDA'S INDONESIA COLLABORATION STRENGTHENS NATIONAL PDMP ECOSYSTEM
  • 5.10.3 ADVANCED VIRAL INACTIVATION IMPROVES PLASMA-DERIVED PRODUCT MANUFACTURING
• 5.11 IMPACT OF 2025 US TARIFFS ON PLASMA FRACTIONATION MARKET
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
  • 5.11.4 IMPACT ON COUNTRY/REGION
    • 5.11.4.1 US
    • 5.11.4.2 Europe
    • 5.11.4.3 Asia Pacific
  • 5.11.5 IMPACT ON END-USE INDUSTRIES
    • 5.11.5.1 Hospitals & specialty clinics
    • 5.11.5.2 Homecare settings & infusion centers
    • 5.11.5.3 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Cohn's cold ethanol plasma fractionation
    • 6.1.1.2 Plasma fractionation by chromatography
    • 6.1.1.3 Plasma separation by centrifugation
    • 6.1.1.4 Plasma separation by depth filtration
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Facilitated subcutaneous infusion systems
    • 6.1.2.2 Liquid-stable high-concentration (20%) formulations
    • 6.1.2.3 Single-use bioprocessing & continuous chromatography
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 AI-driven analytics & smart fractionation yield optimization
    • 6.1.3.2 Next-generation automated plasmapheresis & smart donor center systems
• 6.2 TECHNOLOGY ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 METHODOLOGY
  • 6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
  • 6.3.3 LIST OF KEY PATENTS
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF AI/GEN AI ON PLASMA FRACTIONATION MARKET
  • 6.5.1 TOP USE CASES & MARKET POTENTIAL
  • 6.5.2 BEST PRACTICES IN AI-ENABLED PLASMA FRACTIONATION WORKFLOWS
  • 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN PLASMA FRACTIONATION MARKET
  • 6.5.4 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
  • 6.5.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED PLASMA FRACTIONATION TECHNOLOGIES

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
    • 7.1.2.1 North America
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
    • 7.1.2.4 Rest of the World
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 PLASMA FRACTIONATION MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 IMMUNOGLOBULINS
  • 9.2.1 IVIG
    • 9.2.1.1 Expanding clinical indications, rising immune disorder diagnoses, and advances in IVIG formulations to drive market growth
  • 9.2.2 SCIG
    • 9.2.2.1 Rising preference for home-based treatment, expanding neurological indications, and patient-friendly administration to drive SCIG demand
  • 9.2.3 OTHER IMMUNOGLOBULINS
• 9.3 COAGULATION FACTOR CONCENTRATES
  • 9.3.1 FACTOR VIII
    • 9.3.1.1 Improved hemophilia diagnosis and reliable plasma-derived product supply to boost demand for Factor VIII
  • 9.3.2 FACTOR IX
    • 9.3.2.1 Hemophilia B diagnosis and continued demand for replacement therapy to support Factor IX utilization
  • 9.3.3 VON WILLEBRAND FACTOR
    • 9.3.3.1 Expanded pediatric prophylaxis and increasing access to specialized bleeding disorder care to support market growth
  • 9.3.4 PROTHROMBIN COMPLEX CONCENTRATES (PCC)
    • 9.3.4.1 Rapid anticoagulation reversal and rising emergency-care requirements to aid market growth
  • 9.3.5 FIBRINOGEN CONCENTRATES
    • 9.3.5.1 Rising demand for targeted coagulation replacement to drive global market growth
  • 9.3.6 FACTOR XIII
    • 9.3.6.1 Growing demand for preventive replacement therapy to support market growth
  • 9.3.7 OTHER COAGULATION FACTOR CONCENTRATES
• 9.4 ALBUMIN
  • 9.4.1 RISING DEMAND FOR CRITICAL CARE AND LIVER DISEASE THERAPIES TO BOOST MARKET GROWTH
• 9.5 PROTEASE INHIBITORS
  • 9.5.1 INCREASING AATD DIAGNOSIS AND DEMAND FOR LONG-TERM AUGMENTATION THERAPY TO PROPEL MARKET
• 9.6 OTHER PLASMA PRODUCTS

10 PLASMA FRACTIONATION MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 THERAPEUTICS
  • 10.2.1 STRONG CLINICAL DEMAND FOR PLASMA-DERIVED THERAPIES TO SUSTAIN THERAPEUTICS AS CORE APPLICATION OF PLASMA FRACTIONATION MARKET
• 10.3 ACADEMICS & PRECLINICAL RESEARCH
  • 10.3.1 EXPANDING USE OF HUMAN PLASMA FRACTIONS IN RESEARCH AND BIOPROCESSING TO SUPPORT DEMAND

11 PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA

• 11.1 INTRODUCTION
• 11.2 NEUROLOGY
  • 11.2.1 GROWING UTILIZATION OF PLASMA-DERIVED IMMUNOGLOBULINS IN NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR PLASMA FRACTIONATION
• 11.3 IMMUNOLOGY
  • 11.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCIES AND AUTOIMMUNE DISORDERS TO DRIVE DEMAND FOR PLASMA-DERIVED IMMUNOGLOBULINS
• 11.4 HEMATOLOGY
  • 11.4.1 RISING DEMAND FOR PLASMA-DERIVED COAGULATION FACTORS TO SUPPORT TREATMENT OF BLEEDING DISORDERS
• 11.5 CRITICAL CARE
  • 11.5.1 ESSENTIAL DEMAND FOR ALBUMIN EXPANDERS AND FOUR-FACTOR CONCENTRATE REVERSAL AGENTS TO DRIVE CLINICAL UTILITY IN EMERGENCY SETTINGS
• 11.6 PULMONOLOGY
  • 11.6.1 GROWING DIAGNOSIS OF ALPHA-1 ANTITRYPSIN DEFICIENCY TO SUPPORT DEMAND FOR PLASMA-DERIVED PROTEASE INHIBITORS
• 11.7 HEMATO-ONCOLOGY
  • 11.7.1 INCREASING SUPPORTIVE-CARE REQUIREMENTS IN HEMATOLOGICAL MALIGNANCIES TO SUPPORT UTILIZATION OF PLASMA-DERIVED PRODUCTS
• 11.8 RHEUMATOLOGY
  • 11.8.1 EXPANDING USE OF IMMUNOGLOBULIN THERAPY IN IMMUNE-MEDIATED DISORDERS TO SUPPORT DEMAND FOR PLASMA-DERIVED PRODUCTS
• 11.9 OTHER THERAPEUTIC AREAS

12 PLASMA FRACTIONATION MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 HOSPITALS & SPECIALTY CLINICS
  • 12.2.1 INCREASING UTILIZATION OF PLASMA-DERIVED THERAPIES ACROSS CLINICAL TREATMENT SETTINGS TO DRIVE DEMAND FOR PLASMA FRACTIONATION PRODUCTS
• 12.3 HOME CARE SETTINGS & INFUSION CENTERS
  • 12.3.1 GROWING ADOPTION OF HOME-BASED IMMUNOGLOBULIN ADMINISTRATION TO SUPPORT DEMAND FOR PLASMA-DERIVED THERAPIES
• 12.4 OTHER END USERS

13 PLASMA FRACTIONATION MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 US
    • 13.2.1.1 Expanding plasma collection, fractionation capacity, and immunoglobulin demand to drive US market growth
  • 13.2.2 CANADA
    • 13.2.2.1 Rising immunoglobulin demand and investments in domestic plasma supply to drive market growth
• 13.3 EUROPE
  • 13.3.1 GERMANY
    • 13.3.1.1 Expanding plasma collection infrastructure and rising demand for plasma-derived therapies to drive market growth in Germany
  • 13.3.2 UK
    • 13.3.2.1 Rising immunoglobulin demand, domestic plasma collection, and investments in fractionation capacity to boost market growth
  • 13.3.3 FRANCE
    • 13.3.3.1 Established healthcare infrastructure and public plasma donation model to support access to treatment
  • 13.3.4 ITALY
    • 13.3.4.1 Growing use of immunoglobulins for neurological and immunological disorders to drive demand
  • 13.3.5 SPAIN
    • 13.3.5.1 Growing utilization of albumin for critical care and coagulation factor concentrates for bleeding disorders to support growth
  • 13.3.6 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 CHINA
    • 13.4.1.1 Large domestic donor-plasma collection network and manufacturers focused on expanding product availability to drive growth
  • 13.4.2 JAPAN
    • 13.4.2.1 Highly organized blood donation system and national focus on securing plasma for domestic therapeutic requirements to boost market
  • 13.4.3 INDIA
    • 13.4.3.1 Substantial unmet treatment needs and efforts to improve access to quality-assured plasma-derived medicines to drive growth
  • 13.4.4 SOUTH KOREA
    • 13.4.4.1 Domestic manufacturing expertise with investments in storage infrastructure and overseas contract manufacturing to expand market
  • 13.4.5 AUSTRALIA
    • 13.4.5.1 National self-sufficiency policy linking locally collected plasma with domestic manufacturing and patient supply to position Australia as major hub
  • 13.4.6 VIETNAM
    • 13.4.6.1 Improvements in healthcare access and growing awareness of plasma-derived therapies to support demand
  • 13.4.7 MALAYSIA
    • 13.4.7.1 Dependence on imported plasma-derived therapies to increase focus on plasma collection, contract fractionation, and long-term supply agreements
  • 13.4.8 INDONESIA
    • 13.4.8.1 Large patient population and increasing diagnosis of neurological and immunological disorders to support demand for immunoglobulins
  • 13.4.9 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 BRAZIL
    • 13.5.1.1 Expanding local processing to create opportunities to improve plasma utilization and strengthen Brazil's biopharmaceutical supply chain
  • 13.5.2 MEXICO
    • 13.5.2.1 Broader national strategy to expand pharmaceutical manufacturing and reduce reliance on imported medicines to drive market
  • 13.5.3 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 GCC COUNTRIES
    • 13.6.1.1 Saudi Arabia
      • 13.6.1.1.1 National objective of achieving self-sufficiency in plasma-derived medicines and reducing dependence on imported therapies to aid growth
    • 13.6.1.2 UAE
      • 13.6.1.2.1 Growing investment in pharmaceutical localization and efforts to strengthen national medicine security to boost growth
    • 13.6.1.3 Rest of GCC Countries
  • 13.6.2 TURKEY
    • 13.6.2.1 Domestic fractionation investment, import substitution, and rising demand for plasma-derived therapies to drive growth
  • 13.6.3 EGYPT
    • 13.6.3.1 Domestic plasma self-sufficiency, expanding collection infrastructure, and investment in local fractionation to fuel market
  • 13.6.4 REST OF MIDDLE EAST
• 13.7 AFRICA
  • 13.7.1 INVESTMENTS IN PLASMA COLLECTION, DOMESTIC MANUFACTURING, AND INTERNATIONAL PARTNERSHIPS TO SUPPORT DEVELOPMENT OF MARKET

14 COMPETITIVE LANDSCAPE

• 14.1 OVERVIEW
• 14.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023-2026
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, JANUARY 2023-AUGUST 2026
• 14.3 REVENUE ANALYSIS, 2021-2025
• 14.4 MARKET SHARE ANALYSIS, 2025
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Product footprint
    • 14.5.5.4 Therapeutic area footprint
    • 14.5.5.5 Application footprint
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 14.6.5.1 Detailed list of key startup/SME players
    • 14.6.5.2 Competitive benchmarking of startups/SMEs
• 14.7 COMPANY VALUATION & FINANCIAL METRICS
  • 14.7.1 COMPANY VALUATION
  • 14.7.2 COMPANY VALUATION
• 14.8 BRAND/PRODUCT COMPARISON
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT LAUNCHES
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 CSL
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches
      • 15.1.1.3.2 Expansions
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 GRIFOLS, S.A.
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Product launches
      • 15.1.2.3.2 Deals
      • 15.1.2.3.3 Expansions
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product launches
      • 15.1.3.3.2 Deals
      • 15.1.3.3.3 Expansions
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses & competitive threats
  • 15.1.4 OCTAPHARMA AG
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product launches
      • 15.1.4.3.2 Expansions
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses & competitive threats
  • 15.1.5 KEDRION S.P.A.
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product launches
      • 15.1.5.3.2 Deals
      • 15.1.5.3.3 Expansions
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Key strengths
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses & competitive threats
  • 15.1.6 LFB
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Expansions
  • 15.1.7 ADMA BIOLOGICS, INC.
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Deals
  • 15.1.8 SANQUIN
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Expansions
  • 15.1.9 TAIBANG BIOLOGICAL GROUP CO., LTD.
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Expansions
  • 15.1.10 GC BIOPHARMA CORPORATE
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product launches
      • 15.1.10.3.2 Deals
      • 15.1.10.3.3 Expansions
  • 15.1.11 HUALAN BIOLOGICAL ENGINEERING INC.
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products offered
  • 15.1.12 JAPAN BLOOD PRODUCTS ORGANIZATION
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Product launches
      • 15.1.12.3.2 Expansions
  • 15.1.13 EMERGENT
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products offered
  • 15.1.14 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Deals
  • 15.1.15 INTAS PHARMACEUTICALS LTD.
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Deals
      • 15.1.15.3.2 Expansions
• 15.2 OTHER PLAYERS
  • 15.2.1 BHARAT SERUMS AND VACCINES LIMITED
  • 15.2.2 SK PLASMA
  • 15.2.3 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.
  • 15.2.4 KAMADA PHARMACEUTICALS
  • 15.2.5 CENTURION
  • 15.2.6 PLASMAGEN BIOSCIENCES PVT. LTD.
  • 15.2.7 VIRCHOW BIOTECH
  • 15.2.8 FUSION HEALTHCARE
  • 15.2.9 ICHOR

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH DATA
  • 16.1.1 SECONDARY DATA
    • 16.1.1.1 Key data from secondary sources
  • 16.1.2 PRIMARY DATA
    • 16.1.2.1 Key data from primary sources
    • 16.1.2.2 Key primary participants
    • 16.1.2.3 Breakdown of primary interviews
    • 16.1.2.4 Key industry insights
• 16.2 MARKET SIZE ESTIMATION
  • 16.2.1 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATION, 2025
  • 16.2.2 SEGMENTAL MARKET SIZE ESTIMATION
• 16.3 MARKET GROWTH RATE PROJECTIONS
• 16.4 DATA TRIANGULATION
• 16.5 FACTOR ANALYSIS
• 16.6 RESEARCH ASSUMPTIONS
• 16.7 RESEARCH LIMITATIONS & RISK ASSESSMENT

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS

List of Tables

• TABLE 1 PLASMA FRACTIONATION MARKET: INCLUSIONS & EXCLUSIONS
• TABLE 2 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
• TABLE 3 NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2021-2022
• TABLE 4 PLASMA FRACTIONATION MARKET: PORTER'S FIVE FORCES
• TABLE 5 PLASMA FRACTIONATION MARKET: ROLE OF PLAYERS IN ECOSYSTEM
• TABLE 6 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023-2025 (USD)
• TABLE 7 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
• TABLE 8 IMPORT DATA FOR HS CODE 3002.12-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
• TABLE 9 EXPORT DATA FOR HS CODE 3002.12-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
• TABLE 10 PLASMA FRACTIONATION MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026-MARCH 2027
• TABLE 11 RECIPROCAL TARIFF RATES ADJUSTED BY US
• TABLE 12 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
• TABLE 13 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015-2025
• TABLE 14 LIST OF KEY PATENTS IN PLASMA FRACTIONATION MARKET, 2023-2025
• TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN PLASMA FRACTIONATION MARKET
• TABLE 16 CLIENTS' READINESS TO ADOPT AI-INTEGRATED PLASMA FRACTIONATION TECHNOLOGIES IN PLASMA FRACTIONATION MARKET
• TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
• TABLE 22 KEY BUYING CRITERIA, BY END USER
• TABLE 23 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 24 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 25 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 26 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 27 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 28 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 29 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 30 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 31 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 32 PLASMA FRACTIONATION MARKET FOR IVIG, BY REGION, 2024-2031 (USD MILLION)
• TABLE 33 PLASMA FRACTIONATION MARKET FOR IVIG, 2024-2031 (METRIC TONS)
• TABLE 34 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 35 EUROPE: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 36 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 37 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 38 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 39 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IVIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 40 PLASMA FRACTIONATION MARKET FOR SCIG, BY REGION, 2024-2031 (USD MILLION)
• TABLE 41 PLASMA FRACTIONATION MARKET FOR SCIG, 2024-2031 (METRIC TONS)
• TABLE 42 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 43 EUROPE: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 44 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 45 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 46 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 47 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR SCIG, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 48 PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 49 PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, 2024-2031 (METRIC TONS)
• TABLE 50 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 51 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 52 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 53 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 54 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 55 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 56 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 57 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 58 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 59 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 60 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 61 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 62 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 63 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 64 PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY REGION, 2024-2031 (USD MILLION)
• TABLE 65 PLASMA FRACTIONATION MARKET FOR FACTOR VIII, 2024-2031 (MILLION IU)
• TABLE 66 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 67 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 68 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 69 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 70 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 71 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 72 PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY REGION, 2024-2031 (USD MILLION)
• TABLE 73 PLASMA FRACTIONATION MARKET FOR FACTOR IX, 2024-2031 (MILLION IU)
• TABLE 74 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 75 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 76 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 77 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 78 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 79 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 80 PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY REGION, 2024-2031 (USD MILLION)
• TABLE 81 PLASMA FRACTIONATION MARKET FOR FACTOR VON WILLEBRAND FACTOR, 2024-2031 (MILLION LITER)
• TABLE 82 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 83 EUROPE: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 84 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 85 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 86 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 87 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 88 PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 89 PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, 2024-2031 (MILLION IU)
• TABLE 90 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 91 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 92 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 93 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 94 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 95 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 96 PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 97 PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, 2024-2031 (MILLION IU)
• TABLE 98 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 99 EUROPE: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 100 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 101 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 102 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 103 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 104 PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY REGION, 2024-2031 (USD MILLION)
• TABLE 105 PLASMA FRACTIONATION MARKET FOR FACTOR XIII, 2024-2031 (MILLION IU)
• TABLE 106 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 107 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 108 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 109 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 110 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 111 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 112 PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY REGION, 2024-2031 (USD MILLION)
• TABLE 113 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 114 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 115 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 116 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 117 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 118 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 119 PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2024-2031 (USD MILLION)
• TABLE 120 PLASMA FRACTIONATION MARKET FOR ALBUMIN, 2024-2031 (METRIC TONS)
• TABLE 121 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 122 EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 123 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 124 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 125 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 126 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 127 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 128 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, 2024-2031 (MILLION IU)
• TABLE 129 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 130 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 131 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 132 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 133 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 134 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 135 PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 136 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 137 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 138 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 139 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 140 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 141 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 142 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 143 PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 144 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 145 EUROPE: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 146 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 147 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 148 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 149 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR THERAPEUTICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 150 PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY REGION, 2024-2031 (USD MILLION)
• TABLE 151 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 152 EUROPE: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 153 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 154 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 155 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 156 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR ACADEMICS & PRECLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 157 PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 158 PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY REGION, 2024-2031 (USD MILLION)
• TABLE 159 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 160 EUROPE: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 161 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 162 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 163 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 164 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 165 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY REGION, 2024-2031 (USD MILLION)
• TABLE 166 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 167 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 168 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 169 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 170 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 171 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 172 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY REGION, 2024-2031 (USD MILLION)
• TABLE 173 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 174 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 175 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 176 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 177 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 178 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 179 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY REGION, 2024-2031 (USD MILLION)
• TABLE 180 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 181 EUROPE: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 182 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 183 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 184 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 185 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 186 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY REGION, 2024-2031 (USD MILLION)
• TABLE 187 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 188 EUROPE: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 189 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 190 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 191 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 192 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 193 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY REGION, 2024-2031 (USD MILLION)
• TABLE 194 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 195 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 196 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 197 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 198 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 199 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 200 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY REGION, 2024-2031 (USD MILLION)
• TABLE 201 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 202 EUROPE: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 203 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 204 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 205 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 206 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 207 PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 208 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 209 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 210 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 211 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 212 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 213 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 214 PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 215 PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 216 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 217 EUROPE: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 218 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 219 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 220 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 221 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 222 PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 223 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 224 EUROPE: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 225 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 226 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 227 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 228 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR HOME CARE SETTINGS & INFUSION CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 229 PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
• TABLE 230 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 231 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 232 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 233 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 234 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 235 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 236 PLASMA FRACTIONATION MARKET, BY REGION, 2024-2031 (USD MILLION)
• TABLE 237 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 238 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 239 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 240 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 241 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 242 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 243 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 244 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 245 US: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 246 US: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 247 US: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 248 US: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 249 US: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 250 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 251 CANADA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 252 CANADA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 253 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 254 CANADA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 255 CANADA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 256 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 257 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 258 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 259 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 260 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 261 EUROPE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 262 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 263 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 264 GERMANY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 265 GERMANY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 266 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 267 GERMANY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 268 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 269 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 270 UK: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 271 UK: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 272 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 273 UK: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 274 UK: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 275 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 276 FRANCE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 277 FRANCE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 278 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 279 FRANCE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 280 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 281 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 282 ITALY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 283 ITALY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 284 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 285 ITALY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 286 ITALY: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 287 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 288 SPAIN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 289 SPAIN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 290 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 291 SPAIN: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 292 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 293 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 294 REST OF EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 295 REST OF EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 296 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 297 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 298 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 299 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 300 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 301 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 302 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 303 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 304 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 305 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 306 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 307 CHINA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 308 CHINA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 309 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 310 CHINA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 311 CHINA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 312 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 313 JAPAN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 314 JAPAN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 315 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 316 JAPAN: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 317 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 318 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 319 INDIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 320 INDIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 321 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 322 INDIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 323 INDIA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 324 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 325 SOUTH KOREA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 326 SOUTH KOREA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 327 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 328 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 329 SOUTH KOREA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 330 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 331 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 332 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 333 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 334 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 335 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 336 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 337 VIETNAM: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 338 VIETNAM: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 339 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 340 VIETNAM: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 341 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 342 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 343 MALAYSIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 344 MALAYSIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 345 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 346 MALAYSIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 347 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 348 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 349 INDONESIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 350 INDONESIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 351 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 352 INDONESIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 353 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 354 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 355 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 356 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 357 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 358 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 359 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 360 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 361 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 362 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 363 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 364 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 365 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 366 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 367 BRAZIL: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 368 BRAZIL: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 369 BRAZIL: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 370 BRAZIL: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 371 BRAZIL: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 372 BRAZIL: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 373 MEXICO: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 374 MEXICO: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 375 MEXICO: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 376 MEXICO: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 377 MEXICO: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 378 MEXICO: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 379 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 380 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 381 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 382 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 383 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 384 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 385 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 386 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 387 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 388 MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 389 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 390 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 391 MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 392 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
• TABLE 393 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 394 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 395 GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 396 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 397 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 398 GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 399 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 400 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 401 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 402 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 403 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 404 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 405 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 406 UAE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 407 UAE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 408 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 409 UAE: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 410 UAE: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 411 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 412 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 413 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 414 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 415 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 416 REST OF GCC COUNTRIES: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 417 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 418 TURKEY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 419 TURKEY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 420 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 421 TURKEY: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 422 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 423 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 424 EGYPT: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 425 EGYPT: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 426 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 427 EGYPT: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 428 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 429 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 430 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 431 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 432 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 433 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 434 REST OF MIDDLE EAST: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 435 AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
• TABLE 436 AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 437 AFRICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2024-2031 (USD MILLION)
• TABLE 438 AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
• TABLE 439 AFRICA: PLASMA FRACTIONATION MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
• TABLE 440 AFRICA: PLASMA FRACTIONATION MARKET, BY END USER, 2024-2031 (USD MILLION)
• TABLE 441 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, JANUARY 2023-AUGUST 2026
• TABLE 442 PLASMA FRACTIONATION MARKET: DEGREE OF COMPETITION
• TABLE 443 PLASMA FRACTIONATION MARKET: REGION FOOTPRINT
• TABLE 444 PLASMA FRACTIONATION MARKET: PRODUCT FOOTPRINT
• TABLE 445 PLASMA FRACTIONATION MARKET: THERAPEUTIC AREA FOOTPRINT
• TABLE 446 PLASMA FRACTIONATION MARKET: APPLICATION FOOTPRINT
• TABLE 447 PLASMA FRACTIONATION MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 448 PLASMA FRACTIONATION MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
• TABLE 449 PLASMA FRACTIONATION MARKET: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
• TABLE 450 PLASMA FRACTIONATION MARKET: DEALS, JANUARY 2023-AUGUST 2026
• TABLE 451 PLASMA FRACTIONATION MARKET: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 452 CSL: COMPANY OVERVIEW
• TABLE 453 CSL: PRODUCTS OFFERED
• TABLE 454 CSL: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
• TABLE 455 CSL: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 456 GRIFOLS, S.A.: COMPANY OVERVIEW
• TABLE 457 GRIFOLS, S.A.: PRODUCTS OFFERED
• TABLE 458 GRIFOLS, S.A.: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
• TABLE 459 GRIFOLS, S.A.: DEALS, JANUARY 2023-AUGUST 2026
• TABLE 460 GRIFOLS, S.A.: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 461 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
• TABLE 462 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED
• TABLE 463 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
• TABLE 464 TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS, JANUARY 2023-AUGUST 2026
• TABLE 465 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 466 OCTAPHARMA AG: COMPANY OVERVIEW
• TABLE 467 OCTAPHARMA AG: PRODUCTS OFFERED
• TABLE 468 OCTAPHARMA AG: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
• TABLE 469 OCTAPHARMA AG: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 470 KEDRION S.P.A.: COMPANY OVERVIEW
• TABLE 471 KEDRION S.P.A.: PRODUCTS OFFERED
• TABLE 472 KEDRION S.P.A.: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
• TABLE 473 KEDRION S.P.A.: DEALS, JANUARY 2023-AUGUST 2026
• TABLE 474 KEDRION S.P.A.: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 475 LFB: COMPANY OVERVIEW
• TABLE 476 LFB: PRODUCTS OFFERED
• TABLE 477 LFB: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 478 ADMA BIOLOGICS, INC.: COMPANY OVERVIEW
• TABLE 479 ADMA BIOLOGICS, INC.: PRODUCTS OFFERED
• TABLE 480 ADMA BIOLOGICS, INC.: DEALS, JANUARY 2023-AUGUST 2026
• TABLE 481 SANQUIN: COMPANY OVERVIEW
• TABLE 482 SANQUIN: PRODUCTS OFFERED
• TABLE 483 SANQUIN: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 484 TAIBANG BIOLOGICAL GROUP CO., LTD.: COMPANY OVERVIEW
• TABLE 485 TAIBANG BIOLOGICAL GROUP CO., LTD.: PRODUCTS OFFERED
• TABLE 486 TAIBANG BIOLOGICAL GROUP CO., LTD.: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 487 GC BIOPHARMA CORPORATE: COMPANY OVERVIEW
• TABLE 488 GC BIOPHARMA CORPORATE: PRODUCTS OFFERED
• TABLE 489 GC BIOPHARMA CORPORATE: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
• TABLE 490 GC BIOPHARMA CORPORATE: DEALS, JANUARY 2023-AUGUST 2026
• TABLE 491 GC BIOPHARMA CORPORATE: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 492 HUALAN BIOLOGICAL ENGINEERING INC.: COMPANY OVERVIEW
• TABLE 493 HUALAN BIOLOGICAL ENGINEERING INC.: PRODUCTS OFFERED
• TABLE 494 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY OVERVIEW
• TABLE 495 JAPAN BLOOD PRODUCTS ORGANIZATION: PRODUCTS OFFERED
• TABLE 496 JAPAN BLOOD PRODUCTS ORGANIZATION: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
• TABLE 497 JAPAN BLOOD PRODUCTS ORGANIZATION: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 498 EMERGENT: COMPANY OVERVIEW
• TABLE 499 EMERGENT: PRODUCTS OFFERED
• TABLE 500 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: COMPANY OVERVIEW
• TABLE 501 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: PRODUCTS OFFERED
• TABLE 502 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: DEALS, JANUARY 2023-AUGUST 2026
• TABLE 503 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW
• TABLE 504 INTAS PHARMACEUTICALS LTD.: PRODUCTS OFFERED
• TABLE 505 INTAS PHARMACEUTICALS LTD.: DEALS, JANUARY 2023-AUGUST 2026
• TABLE 506 INTAS PHARMACEUTICALS LTD.: EXPANSIONS, JANUARY 2023-AUGUST 2026
• TABLE 507 BHARAT SERUMS AND VACCINES LIMITED: COMPANY OVERVIEW
• TABLE 508 SK PLASMA: COMPANY OVERVIEW
• TABLE 509 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
• TABLE 510 KAMADA PHARMACEUTICALS: COMPANY OVERVIEW
• TABLE 511 CENTURION: COMPANY OVERVIEW
• TABLE 512 PLASMAGEN BIOSCIENCES PVT. LTD.: COMPANY OVERVIEW
• TABLE 513 VIRCHOW BIOTECH: COMPANY OVERVIEW
• TABLE 514 FUSION HEALTHCARE: COMPANY OVERVIEW
• TABLE 515 ICHOR: COMPANY OVERVIEW
• TABLE 516 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
• TABLE 517 RISK ASSESSMENT

List of Figures

• FIGURE 1 PLASMA FRACTIONATION MARKET SEGMENTATION & REGIONS CONSIDERED
• FIGURE 2 PLASMA FRACTIONATION MARKET: YEARS CONSIDERED
• FIGURE 3 MARKET SCENARIO
• FIGURE 4 GLOBAL PLASMA FRACTIONATION MARKET, 2024-2031
• FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2023-2026
• FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PLASMA FRACTIONATION MARKET
• FIGURE 7 HIGH-GROWTH SEGMENTS IN PLASMA FRACTIONATION MARKET, 2026-2031
• FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PLASMA FRACTIONATION MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
• FIGURE 9 RISING ADOPTION OF PLASMA-DERIVED PRODUCTS IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET GROWTH
• FIGURE 10 THERAPEUTICS ACCOUNTED FOR LARGEST SHARE OF PLASMA FRACTIONATION MARKET IN NORTH AMERICA IN 2025
• FIGURE 11 CHINA AND GERMANY LIKELY TO BE FASTEST-GROWING MARKETS IN GLOBAL PLASMA FRACTIONATION MARKET DURING FORECAST PERIOD
• FIGURE 12 THERAPEUTICS TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 13 PLASMA FRACTIONATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 14 PLASMA FRACTIONATION MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 15 PLASMA FRACTIONATION MARKET: VALUE CHAIN ANALYSIS
• FIGURE 16 PLASMA FRACTIONATION MARKET: ECOSYSTEM ANALYSIS
• FIGURE 17 AVERAGE SELLING PRICE OF PRODUCTS, 2025 (USD)
• FIGURE 18 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
• FIGURE 19 PLASMA FRACTIONATION MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 20 INVESTMENT & FUNDING SCENARIO, 2024-2026 (USD MILLION)
• FIGURE 21 PATENT APPLICATIONS IN PLASMA FRACTIONATION MARKET, JANUARY 2015-DECEMBER 2025
• FIGURE 22 IMPACT OF AI/GEN AI ON PLASMA FRACTIONATION MARKET
• FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
• FIGURE 24 KEY BUYING CRITERIA, BY END USER
• FIGURE 25 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT
• FIGURE 26 ASIA PACIFIC: PLASMA FRACTIONATION MARKET SNAPSHOT
• FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2021-2025 (USD MILLION)
• FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2025
• FIGURE 29 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
• FIGURE 30 PLASMA FRACTIONATION MARKET: COMPANY FOOTPRINT
• FIGURE 31 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
• FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 33 EV/EBITDA OF KEY VENDORS
• FIGURE 34 PLASMA FRACTIONATION MARKET: BRAND/PRODUCT COMPARISON
• FIGURE 35 CSL: COMPANY SNAPSHOT (2025)
• FIGURE 36 GRIFOLS, S.A.: COMPANY SNAPSHOT (2025)
• FIGURE 37 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2025)
• FIGURE 38 OCTAPHARMA AG: COMPANY SNAPSHOT (2025)
• FIGURE 39 KEDRION S.P.A.: COMPANY SNAPSHOT (2025)
• FIGURE 40 ADMA BIOLOGICS, INC.: COMPANY SNAPSHOT (2025)
• FIGURE 41 SANQUIN: COMPANY SNAPSHOT (2025)
• FIGURE 42 GC BIOPHARMA CORPORATE: COMPANY SNAPSHOT (2025)
• FIGURE 43 EMERGENT: COMPANY SNAPSHOT (2025)
• FIGURE 44 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: COMPANY SNAPSHOT (2025)
• FIGURE 45 PLASMA FRACTIONATION MARKET: RESEARCH DESIGN
• FIGURE 46 PLASMA FRACTIONATION MARKET: BREAKDOWN OF PRIMARIES
• FIGURE 47 PLASMA FRACTIONATION MARKET: INSIGHTS FROM PRIMARIES
• FIGURE 48 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATION, 2025
• FIGURE 49 PLASMA FRACTIONATION MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025)
• FIGURE 50 ILLUSTRATIVE EXAMPLE OF CSL: REVENUE ANALYSIS (2025)
• FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
• FIGURE 52 PLASMA FRACTIONATION MARKET: CAGR PROJECTIONS
• FIGURE 53 PLASMA FRACTIONATION MARKET: DATA TRIANGULATION